{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:21:54Z","timestamp":1791328914817,"version":"4.3.1"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Bayer HealthCare AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To investigate the safety and potential efficacy of the novel non-steroidal mineralocorticoid receptor antagonist finerenone in patients with worsening chronic heart failure and reduced left ventricular ejection fraction (HFrEF) and at high risk of hyperkalaemia and worsening renal dysfunction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF; NCT01807221) is a multicentre, randomized, double-blind, active-comparator-controlled, six-parallel-group, phase 2b dose-finding study. In total, 1060 patients with HFrEF and concomitant type 2 diabetes mellitus and\/or chronic kidney disease (CKD) will be randomized within 7\u2009days of emergency presentation to hospital for worsening chronic HF to receive finerenone (one of five doses in the range 2.5\u201320.0\u2009mg once daily) or eplerenone (25\u2009mg every second day to 50\u2009mg once daily for 90\u2009days). The primary objective is to investigate the safety and potential efficacy (measured as the percentage of individuals with a decrease in plasma N-terminal pro-B-type natriuretic peptide [NT-proBNP] of more than 30% relative to baseline at day 90\u2009\u00b1\u20092) of different oral doses of finerenone compared with eplerenone. Other objectives are to assess the effects of finerenone on a composite clinical endpoint (death from any cause, cardiovascular hospitalizations, or emergency presentations for worsening chronic HF), and on changes in health-related quality of life from baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ARTS-HF is the first phase 2b clinical trial to investigate the effects of finerenone on plasma NT-proBNP in a high-risk population of patients who have worsening chronic HF with type 2 diabetes mellitus and\/or CKD presenting at the emergency department.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.218","type":"journal-article","created":{"date-parts":[[2015,2,12]],"date-time":"2015-02-12T13:59:27Z","timestamp":1423749567000},"page":"224-232","source":"Crossref","is-referenced-by-count":82,"title":["Rationale and Design of Mineralocorticoid Receptor Antagonist Tolerability Study-Heart Failure (ARTS-HF): A Randomized Study of Finerenone vs. Eplerenone in Patients who have Worsening Chronic Heart Failure with Diabetes and\/or Chronic Kidney Disease"],"prefix":"10.1093","volume":"17","author":[{"given":"Bertram","family":"Pitt","sequence":"first","affiliation":[{"name":"University of Michigan Medical School , 1500 E Medical Center Drive, 3910 Tauman Ctr, Ann Arbor, MI, 48109 0366 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[{"name":"Department of Innovative Clinical Trials, University Medical Centre G\u00f6ttingen , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[{"name":"Universit\u00e4tskliniken des Saarlandes , Klinik f\u00fcr Innere Medizin III, Homburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai","family":"Gheorghiade","sequence":"additional","affiliation":[{"name":"Feinberg School of Medicine, Northwestern University , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"K\u00f8ber","sequence":"additional","affiliation":[{"name":"Heart Centre, Rigshospitalet, University of Copenhagen \u00a0","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Krum","sequence":"additional","affiliation":[{"name":"Centre of Cardiovascular Research and Education in Therapeutics, Monash University , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo P.","family":"Maggioni","sequence":"additional","affiliation":[{"name":"Research Centre of the Italian Association of Hospital Cardiologists , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[{"name":"Medical University, Clinical Military Hospital , Wroc\u0142aw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A.","family":"Voors","sequence":"additional","affiliation":[{"name":"University Medical Centre Groningen , Groningen ,","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"CHU Department of Cardiology, Universit\u00e9 de Lorraine , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Nowack","sequence":"additional","affiliation":[{"name":"Global Clinical Development, Bayer HealthCare AG , Leverkusen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So-Young","family":"Kim","sequence":"additional","affiliation":[{"name":"Global Clinical Development, Bayer HealthCare AG , Leverkusen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Pieper","sequence":"additional","affiliation":[{"name":"M.A.R.C.O. GmbH & Co. KG , D\u00fcsseldorf ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Kimmeskamp-Kirschbaum","sequence":"additional","affiliation":[{"name":"Global Research & Development Statistics, Bayer HealthCare AG , Leverkusen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Attikon University Hospital , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,2,10]]},"reference":[{"key":"2026011921082656100_ejhf218-bib-0001","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026011921082656100_ejhf218-bib-0002","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026011921082656100_ejhf218-bib-0003","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.cardfail.2012.02.005","article-title":"Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee","volume":"18","author":"Butler","year":"2012","journal-title":"J Card Fail"},{"key":"2026011921082656100_ejhf218-bib-0004","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs105","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2026011921082656100_ejhf218-bib-0005","first-page":"e240","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"2026011921082656100_ejhf218-bib-0006","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"2026011921082656100_ejhf218-bib-0007","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","article-title":"Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure)","volume":"62","author":"Eschalier","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026011921082656100_ejhf218-bib-0008","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1001\/jama.2009.1493","article-title":"Use of aldosterone antagonists in heart failure","volume":"302","author":"Albert","year":"2009","journal-title":"JAMA"},{"key":"2026011921082656100_ejhf218-bib-0009","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ejheart.2008.01.014","article-title":"Acute heart failure in the emergency department: short and long-term outcomes of elderly patients with heart failure","volume":"10","author":"Ezekowitz","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2026011921082656100_ejhf218-bib-0010","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1001\/jama.2011.1510","article-title":"Hospitalizations for heart failure in the United States\u2212a sign of hope","volume":"306","author":"Gheorghiade","year":"2011","journal-title":"JAMA"},{"key":"2026011921082656100_ejhf218-bib-0011","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/jama.2011.836","article-title":"Improving postdischarge outcomes in patients hospitalized for acute heart failure syndromes","volume":"305","author":"Gheorghiade","year":"2011","journal-title":"JAMA"},{"key":"2026011921082656100_ejhf218-bib-0012","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/ejhf.71","article-title":"Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT","volume":"16","author":"Skali","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026011921082656100_ejhf218-bib-0013","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/eurjhf\/hft050","article-title":"EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot)","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026011921082656100_ejhf218-bib-0014","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/eurjhf\/hfq154","article-title":"EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot)","volume":"12","author":"Maggioni","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026011921082656100_ejhf218-bib-0015","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.amjcard.2010.07.018","article-title":"Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease","volume":"106","author":"Edwards","year":"2010","journal-title":"Am J Cardiol"},{"key":"2026011921082656100_ejhf218-bib-0016","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective non-steroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026011921082656100_ejhf218-bib-0017"},{"key":"2026011921082656100_ejhf218-bib-0018","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94\u20138862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"B\u00e4rfacker","year":"2012","journal-title":"ChemMedChem"},{"key":"2026011921082656100_ejhf218-bib-0019","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"2026011921082656100_ejhf218-bib-0020","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ijcard.2006.10.009","article-title":"Serial NT-proBNP monitoring and outcomes in outpatients with decompensation of heart failure","volume":"120","author":"Bayes-Genis","year":"2007","journal-title":"Int J Cardiol"},{"key":"2026011921082656100_ejhf218-bib-0021","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jacc.2008.04.069","article-title":"Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial)","volume":"52","author":"Masson","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026011921082656100_ejhf218-bib-0022","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/eurheartj\/ehn023","article-title":"Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients","volume":"29","author":"Pascual-Figal","year":"2008","journal-title":"Eur Heart J"},{"key":"2026011921082656100_ejhf218-bib-0023","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1161\/CIRCOUTCOMES.110.958009","article-title":"Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life","volume":"4","author":"Allen","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026011921082656100_ejhf218-bib-0024","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/eurjhf\/hfq019","article-title":"Critical elements of clinical follow-up after hospital discharge for heart failure: insights from the EVEREST trial","volume":"12","author":"Dunlay","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026011921082656100_ejhf218-bib-0025","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","article-title":"Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics","volume":"350","author":"Kolkhof","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"2026011921082656100_ejhf218-bib-0026","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3389\/fphar.2013.00115","article-title":"PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy","volume":"4","author":"Orena","year":"2013","journal-title":"Front Pharmacol"},{"key":"2026011921082656100_ejhf218-bib-0027","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ejheart.2006.10.005","article-title":"Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker","volume":"9","author":"Berry","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"2026011921082656100_ejhf218-bib-0028","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ahj.2004.07.036","article-title":"Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure","volume":"149","author":"Frantz","year":"2005","journal-title":"Am Heart J"},{"key":"2026011921082656100_ejhf218-bib-0029","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/eurheartj\/ehl505","article-title":"Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony","volume":"28","author":"Fruhwald","year":"2007","journal-title":"Eur Heart J"},{"key":"2026011921082656100_ejhf218-bib-0030","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1161\/01.CIR.0000143059.68996.A7","article-title":"Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial","volume":"110","author":"Hartmann","year":"2004","journal-title":"Circulation"},{"key":"2026011921082656100_ejhf218-bib-0031","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/S0735-1097(02)02304-5","article-title":"Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors","volume":"40","author":"Maggioni","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2026011921082656100_ejhf218-bib-0032","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1161\/CIRCULATIONAHA.108.809194","article-title":"Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study","volume":"119","author":"Iraqi","year":"2009","journal-title":"Circulation"},{"key":"2026011921082656100_ejhf218-bib-0033","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0735-1097(01)01116-0","article-title":"Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure","volume":"37","author":"Tsutamoto","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"2026011921082656100_ejhf218-bib-0034","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1161\/CIRCHEARTFAILURE.109.906909","article-title":"Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction","volume":"3","author":"Udelson","year":"2010","journal-title":"Circ Heart Fail"},{"key":"2026011921082656100_ejhf218-bib-0035","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/jama.2013.1954","article-title":"Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial","volume":"309","author":"Gheorghiade","year":"2013","journal-title":"JAMA"},{"key":"2026011921082656100_ejhf218-bib-0036","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2459\/JCM.0b013e3282f447ae","article-title":"NT-ProBNP reduction percentage during hospital stay predicts long-term mortality and readmission in heart failure patients","volume":"9","author":"Verdiani","year":"2008","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2026011921082656100_ejhf218-bib-0037","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1161\/01.CIR.0000144310.04433.BE","article-title":"N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients","volume":"110","author":"Bettencourt","year":"2004","journal-title":"Circulation"},{"key":"2026011921082656100_ejhf218-bib-0038","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1161\/CIRCHEARTFAILURE.109.868513","article-title":"Serum cortisol as a useful predictor of cardiac events in patients with chronic heart failure: the impact of oxidative stress","volume":"2","author":"Yamaji","year":"2009","journal-title":"Circ Heart Fail"},{"key":"2026011921082656100_ejhf218-bib-0039","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ahj.2010.04.024","article-title":"Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1(c) levels in patients with chronic heart failure","volume":"160","author":"Yamaji","year":"2010","journal-title":"Am Heart J"},{"key":"2026011921082656100_ejhf218-bib-0040","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","article-title":"ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur Heart J"},{"key":"2026011921082656100_ejhf218-bib-0041","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIR.0b013e31820f2f3e","article-title":"2011 ACCF\/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina\/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"123","author":"Wright","year":"2011","journal-title":"Circulation"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.218","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/17\/2\/224\/66423130\/eurjhf_17_2_224.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/17\/2\/224\/66423130\/eurjhf_17_2_224.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:08:40Z","timestamp":1768874920000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/17\/2\/224\/8426559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,1]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,2,10]]},"published-print":{"date-parts":[[2015,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.218","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725355266.793521191","asserted-by":"object"}]},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,2]]},"published":{"date-parts":[[2015,2,1]]}}}